Skip to main
NBP

NovaBridge Biosciences (NBP) Stock Forecast & Price Target

NovaBridge Biosciences (NBP) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NovaBridge Biosciences is a biotechnology platform that combines business development and clinical research to identify and advance pharmaceutical assets. This innovative company has a robust pipeline, with three clinical stage programs, and their core product, givastomig, has the potential to be a game-changing treatment for gastric cancer and other gastrointestinal malignancies. Furthermore, their VIS101 asset has demonstrated a durability-first approach, with prolonged target suppression and potentially longer dosing intervals, which could be a key differentiator in the market. Overall, NovaBridge Biosciences has a strong outlook with upcoming catalysts and a promising pipeline, making it an attractive investment opportunity.

Bears say

NovaBridge Biosciences is making progress with their clinical and regulatory advances, but the company's overall potential is still not fully appreciated by investors. However, as discussions at AACR 2026 have highlighted, their lead asset givastomig is differentiated in gastric and gastroesophageal cancers and is expected to enter Phase 3 clinical trials soon. Questions remain regarding the patient population and dosing for this asset, as well as the viability of their subsidiary Visara's VEGF-A x ANG-2 tetravalent peptibody for nAMD, but the company's restructuring efforts and FDA endorsements build confidence in their ability to execute successful global clinical programs.

NovaBridge Biosciences (NBP) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NovaBridge Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NovaBridge Biosciences (NBP) Forecast

Analysts have given NovaBridge Biosciences (NBP) a Strong Buy based on their latest research and market trends.

According to 1 analysts, NovaBridge Biosciences (NBP) has a Strong Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NovaBridge Biosciences (NBP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.